<DOC>
	<DOCNO>NCT02199041</DOCNO>
	<brief_summary>In study , participant high-risk hematologic malignancy undergo hematopoietic cell transplantation ( HCT ) , suitable human leukocyte antigen ( HLA ) -matched related/sibling donor ( MSD ) , match unrelated donor ( MURD ) killer-immunoglobulin receptor ( KIR ) ligand mismatch haploidentical donor identify , receive combine T cell deplete ( TCD ) haploidentical peripheral blood stem cell ( PBSC ) unrelated umbilical cord blood transplantation ( UCBT ) use total lymphoid irradiation ( TLI ) base preparative regimen . Primary objective : - To estimate incidence donor derive neutrophil engraftment day +42 post-transplant participant high-risk hematologic malignancy undergo total lymphoid irradiation ( TLI ) -based hematopoietic cell transplantation ( HCT ) use T cell deplete ( TCI ) haploidentical donor peripheral blood stem cell ( PBSC ) donor combine unrelated umbilical cord blood ( UCB ) donor . Secondary objective : - Estimate incidence malignant relapse , event-free survival ( EFS ) , overall survival ( OS ) one-year post-transplantation . - Estimate incidence severity acute chronic graft versus host disease ( GVHD ) first 100 day transplantation . - Estimate incidence secondary graft failure transplant relate mortality ( TRM ) transplant relate morbidity first 100 day HCT .</brief_summary>
	<brief_title>Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell Unrelated Umbilical Cord Blood Transplantation Patients With Hematologic Malignancies Using Total Lymphoid Irradiation Based Preparative Regimen</brief_title>
	<detailed_description>Prior stem cell infusion , participant receive preparative regimen total lymphoid irradiation ( TLI ) , fludarabine , cyclophosphamide , melphalan , thiotepa prepare bone marrow . Thereafter , receive hematopoietic cell graft haploidentical donor unrelated umbilical cord blood donor . Post-transplantation immunosuppressive treatment include tacrolimus mycophenolate mofetil .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion CriteriaTransplant Recipient : Age le equal 21 year old . Does suitable MSD volunteer MUD available necessary time stem cell donation . Has suitable partially HLAmatched ( ≥ 3 6 ) family member donor . Has partially HLAmatched single UCB unit ( ≥ 4 6 ) adequate cell dose . UCB unit must fulfill eligibility outline 21 CFR 1271 agency guidance . Highrisk hematologic malignancy . High risk ALL CR1 . ( Examples include , limited ( 9 ; 22 ) , hypodiploid , , M2 great marrow end induction , infant MLL fusion ( 4 ; 11 ) . ALL High risk CR2 . ( Examples include limited ( 9 ; 22 ) , BM relapse &lt; 36 mo CR1 , TALL , early ( &lt; 6mo CR1 ) isolate CNS relapse . ) ALL CR3 subsequent . AML high risk CR1 . ( Examples include limited precede MDS , 5q , 5 , 7 , FAB M6 , FAB M7 ( 1 ; 22 ) , MRD ≥ 5 % day 22 ( AML08 ) , M3 marrow induction 1 , M2 marrow two cycle induction , FLT3ITD . ) AML CR2 subsequent . Therapy related AML , prior malignancy CR &gt; 12mo MDS , primary secondary NK cell , biphenotypic , undifferentiated leukemia CR1 subsequent . CML accelerate phase , chronic phase persistent molecular positivity intolerance tyrosine kinase inhibitor . Hodgkin lymphoma CR2 subsequent failure prior autologous HCT , unable mobilize stem cell autologous HCT . NonHodgkin lymphoma CR2 subsequent . JMML Refractory hematologic malignancy ( ALL , AML , CML blast crisis , Hodgkin nonHodgkin lymphoma ) due chemoresistant relapse primary induction failure . All patient evidence CNS leukemia must treat CNS CR eligible study . Patient must fulfill pretransplant evaluation : Cardiac Function : Left ventricular ejection fraction ( LVEF ) ≥ 40 % shorten fraction ( SF ) ≥ 25 % . Creatinine clearance ( CrCL ) glomerular filtration rate ( GFR ) ≥ 50 ml/min/1.73m2 . Forced vital capacity ( FVC ) ≥ 50 % predict value pulse oximetry ( Pox ) ≥ 92 % room air . Karnofsky Lansky performance score ≥ 50 ( See APPENDIX A ) . Bilirubin ≤ 3 time upper limit normal age . Alanine aminotransferase ( ALT ) ≤ 5x upper limit normal age . Aspartate aminotransferase ( AST ) ≤ 5x upper limit normal age . Exclusion Criteria Transplant Recipient : Patient suitable MSD , volunteer MURD , KIR mismatch haploidentical donor available necessary time stem cell donation . Patient active malignancy one HCT indicate . Patient pregnant confirm positive serum urine pregnancy test within 14 day prior enrollment . Patient breast feeding . Patient Down Syndrome . Patient current uncontrolled bacterial , fungal , viral infection per judgment PI . Inclusion criterion haploidentical donor At least single haplotype match ( ≥ 3 6 ) family member At least 18 year age . HIV negative . Not pregnant confirm negative serum urine pregnancy test within 14 day prior enrollment ( female ) . Not breast feed . Regarding eligibility , identify either : Completed process donor eligibility determination outline 21 CFR 1271 agency guidance ; OR Does meet 21 CFR 1271 eligibility requirement , declaration urgent medical need complete principal investigator physician subinvestigator per 21 CFR 1271 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cord Blood</keyword>
	<keyword>Haploidentical</keyword>
	<keyword>Reduced Intensity Regimen</keyword>
</DOC>